Gogoro Inc vs Liquidia Corporation Common Stock — how do they compare? Gogoro Inc trades at $2.99 (market cap $65.04M), while Liquidia Corporation Common Stock trades at $34.26 (market cap $2.40B). The key difference: Liquidia Corporation Common Stock is far larger — about 36.9× Gogoro Inc's market cap, and Gogoro Inc is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Liquidia Corporation Common Stock for 0 Days on average.
| GGR | LQDA | |
|---|---|---|
Market Cap | $65.04M | $2.40B |
Volume | 21,493 | 2,857,547 |
Sector | Consumer Cyclical | Health |
52-Week High | $4.66 | $91.03 |
52-Week Low | $2.20 | $22.02 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $351.48M | $2.30B |
Signals from Pluang's Aura AI — not financial advice
GGR trades at $3.24, up 2.53% with a bullish technical signal despite negative profitability metrics. The company reported $281.48M revenue for 2025 but a net loss of $79.97M, though losses are projected to narrow in 2026. Recent developments include $61.8M in new equity investments and board appointments to strengthen governance. Technical indicators show bullish momentum with support at $3.00.
While technical momentum appears positive, fundamental challenges persist with negative margins and cash flow. The investment case hinges on Gogoro's ability to achieve profitability amid expansion costs. Analyst consensus remains cautious with 100% hold ratings, suggesting investors await clearer profitability signals before committing.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →